GlassScriptPhysician profile
Thadis C Cox
NPI 1669482436
$4,196.85
in general payments reported to CMS, 2019-2025
31 companies · $1,536 in 2025
The $1,536 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $314 · 2021: $235 · 2022: $460 · 2023: $483 · 2024: $716 · 2025: $1,536.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,609 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,608.97 |
| Education | $125.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.51 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $629.17 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $419.45 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $229.86 | 2021-2025 | Entyvio, Aralast |
| Madrigal Pharmaceuticals | $208.70 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $207.33 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $173.51 | 2022-2025 | Dupixent |
| Evoke Pharma, INC. | $90.81 | 2022-2024 | Gimoti |
| Echosens North America, INC. | $85.49 | 2024 | Fibroscan |
| Phathom Pharmaceuticals, INC. | $78.57 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $73.20 | 2024-2025 | Omvoh, Zepbound |
| Braintree Laboratories, INC. | $65.35 | 2025 | Suflave |
| Redhill Biopharma INC. | $55.16 | 2020 | |
| Ferring Pharmaceuticals INC. | $52.72 | 2023-2025 | Rebyota |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.12 | 2020-2023 | Cyltezo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $41.50 | 2025 | Iqirvo |
| Allergan, INC. | $40.37 | 2019 | |
| Shionogi INC | $32.16 | 2019 | |
| Nestle Healthcare Nutrition INC. | $30.28 | 2022-2023 | |
| Intercept Pharmaceuticals, INC. | $27.70 | 2019-2025 | |
| Gilead Sciences, INC. | $25.08 | 2019-2020 | |
| Grifols USA, LLC | $23.30 | 2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $20.44 | 2023 | Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $20.17 | 2025 | |
| Novo Nordisk INC | $18.63 | 2025 | Wegovy |
| Genmab U.S., INC. | $18.41 | 2024 | Tivdak |
| Olympus America INC. | $17.61 | 2024 | Evis Exera III Colonovideoscope |
| Pfizer INC. | $16.77 | 2025 | |
| Avanos Medical | $16.02 | 2024 | Enfit |
| Electromed, INC. | $14.00 | 2019 | |
| Daiichi Sankyo INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thadis Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.